๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Safed
Clinical trial register · Israel

Clinical Trials in Safed, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Israel and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 2428 matching records held by the registry are in this view. Synced 26 Sep 2026, 19:47 UTC
2428
Studies in scope
all four open statuses
1246
Recruiting now
open to new participants
455
Lead sponsors
across recruiting studies
Top sites
Jerusalem 843 Haifa 736 Tel Aviv 685 Ramat Gan 651 Petah Tikva 612
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AbbVie5 Merck Sharp & Dohme LLC3 Sanofi3 Exelixis2 Cytokinetics2
Site location
Jerusalem843 Haifa736 Tel Aviv685 Ramat Gan651 Petah Tikva612
All 102 locations
Target enrolment
to

Trials with a site in Safed

34 of 2428 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Israel
Start
Recruiting
A Study to Investigate the Efficacy, Safety, and Pharmacokinetics of Oral Rilzabrutinib Compared With Placebo in Participants 18 Years of Age and Older With Warm Autoimmune Hemolytic Anemia
NCT07086976Autoimmune Haemolytic Anaemia
DrugRilzabrutinib
Sanofi
Phase 3
90
Afula, Haifa, Kefar Sava, Safed, Tel Aviv
2025-08-18
Recruiting
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
NCT07044336Endometrial Cancer, Malignant Solid Tumour
DrugsAdriamycin·Taxol·Doxorubicin·Paclitaxel
AstraZeneca
Phase 3
800
Ashdod, Hadera, Haifa, Holon, Jerusalem, Nahariya, Ramat Gan, Safed
2025-08-01
Active, closed
Extension Study of Sotatercept in People With Pulmonary Hypertension (MK-7962-023)
NCT06814145Hypertension, Pulmonary
DrugSotatercept
Merck Sharp & Dohme LLC
Phase 2
440
Haifa, Holon, Jerusalem, Kfar Saba, Safed
2025-04-16
Recruiting
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
NCT06890884Lymphoma, Large B-Cell, Diffuse
DrugsRituximab Biosimilar·Zilovertamab vedotin·Polatuzumab Vedotin·Prednisolone
Merck Sharp & Dohme LLC
Phase 2
594
Beersheba, Haifa, Holon, Jerusalem, Petah Tikva, Ramat Gan, Safed, Tel Aviv
2025-04-11
Recruiting
The Role of FAPI PET-CT in Diagnosing Endometriosis
NCT06792318Endometriosis
Ziv Hospital
Not applicable
30
Safed
2025-03
Recruiting
A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE)
NCT06858579Chronic Inflammatory Demyelinating Polyneuropathy
DrugClaseprubart
Dianthus Therapeutics
Phase 3
256
Beersheba, Haifa, Safed
2025-02-10
Recruiting
Efficacy and Safety of Zelpultide Alfa in Preterm Neonates at High Risk of Developing Bronchopulmonary Dysplasia (BPD)
NCT06897839Bronchopulmonary Dysplasia
Airway Therapeutics, Inc.
Phase 2/3
366
Haifa, Jerusalem, Safed
2025-02-03
Recruiting
A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer
NCT06319820Non-Muscle Invasive Bladder Neoplasms
DrugGemcitabine
Janssen Research & Development, LLC
Phase 3
641
Haifa, Jerusalem, Ramat Gan, Safed, Tel Aviv
2024-04-18
Active, closed
A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.
NCT06372145Relapsing Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Progressive Relapsing Multiple Sclerosis
DrugTeriflunomide
Sanofi
Phase 3
2,500
Haifa, Rehovot, Safed, Tel Litwinsky
2024-04-16
Active, closed
A Phase 2 Study to Evaluate DNTH103 in Adults With Generalized Myasthenia Gravis (MAGIC)
NCT06282159Myasthenia Gravis, Generalized
DrugClaseprubart
Dianthus Therapeutics
Phase 2
65
Haifa, Ramat Gan, Safed
2024-02-23
Active, closed
Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis
NCT06141473Multiple Sclerosis
DrugsCholestyramine·Activated Charcoal·Teriflunomide·Frexalimab
Sanofi
Phase 3
1,655
Haifa, Ramat Gan, Safed
2023-12-13
Active, closed
Study to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)
NCT06122779Heart Failure
DrugBMS-986435
Bristol-Myers Squibb
Phase 2
227
Jerusalem, Beersheba, Beโ€™er Yaโ€˜aqov, Haifa, Petah Tikva, Rehovot, Safed
2023-11-07
Active, closed
A Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM)
NCT06081894Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy
DrugAficamten
Cytokinetics
Phase 3
500
Ashkelon, Jerusalem, Kfar Saba, Ramat Gan, Safed
2023-08-31
By invitation
A Study to Provide Access to Mitapivat for Participants Who Previously Participated in an Agios-Sponsored Mitapivat Study
NCT05777993Pyruvate Kinase Deficiency, Anemia, Hemolytic, Sickle Cell Disease, Thalassemia
DrugMitapivat
Agios Pharmaceuticals, Inc.
Phase 4
59
Haifa, Safed
2023-07-06
Active, closed
Telepsychiatry to Enable Expedited Disposition of Psychiatric Emergencies
NCT05771545Psychiatric Emergency
Hebrew University of Jerusalem
Observational
959
Afula, Jerusalem, Pardรฉs Hฬฑanna Karkur, Petah Tikva, Safed, Tel Aviv, Tsur Moshe
2023-07-01
Active, closed
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy
NCT05889182Hidradenitis Suppurativa
DrugUpadacitinib
AbbVie
Phase 3
1,328
Petah Tikva, Safed, Ramat Gan, Tel Aviv, Haifa
2023-06-21
Recruiting
POST URS Chemotherapy Instillation
NCT06167057UTUC
Carmel Medical Center
Not applicable
264
Ashdod, Beersheba, Beโ€™er Yaโ€˜aqov, Haifa, Petah Tikva, Rehovot, Safed, Tel Aviv
2023-04-17
Active, closed
A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE
NCT05702034Ischemic Stroke; Ischemic Attack, Transient
DrugMilvexian
Janssen Research & Development, LLC
Phase 3
12,523
Beersheba, Haifa, Jerusalem, Naharya, Petah Tikva, Ramat Gan, Safed, Tel Aviv
2023-02-15
Active, closed
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma
NCT05409066Follicular Lymphoma (FL)
DrugsEpcoritamab·Lenalidomide·Rituximab
Genmab
Phase 3
549
แบ”erifin, Jerusalem, Safed, Ramat Gan, Tel Aviv, Haifa, Petah Tikva
2022-09-20
Active, closed
Safety and Pharmacokinetics Study of a Modified Tafasitamab IV Dosing Regimen Combined With Lenalidomide in R-R DLBCL Patients
NCT05222555Diffuse Large B Cell Lymphoma
DrugsTafasitamab·Lenalidomide
Incyte Corporation
Phase 1/2
53
Beersheba, Beโ€™er Yaโ€˜aqov, Haifa, Jerusalem, Safed
2022-07-19
Recruiting
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
NCT04928846Non Small Cell Lung Cancer
DrugsTelisotuzumab vedotin·Docetaxel
AbbVie
Phase 3
768
Safed, Beersheba, Holon, Tel Aviv
2022-03-25
Active, closed
A Study Evaluating the Efficacy and Safety of Mitapivat (AG-348) in Participants With Sickle Cell Disease (RISE UP)
NCT05031780Sickle Cell Disease
DrugMitapivat
Agios Pharmaceuticals, Inc.
Phase 2/3
286
Afula, Haifa, Safed
2022-02-11
Active, closed
A Study to Assess Real-World Use, Safety, and Effectiveness of Oral Upadacitinib in Adult and Adolescent (>=12 Years Old) Participants With Atopic Dermatitis
NCT05081557Atopic Dermatitis
AbbVie
Observational
873
Rehovot, Afula, Haifa, Jerusalem, Safed, Ashkelon, Ramat Gan, Tel Aviv
2021-11-17
By invitation
Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Aficamten in Adults With HCM
NCT04848506Symptomatic Hypertrophic Cardiomyopathy (HCM)
DrugAficamten
Cytokinetics
Phase 2/3
900
Ashkelon, Jerusalem, Kfar Saba, Ramat Gan, Safed
2021-05-06
Active, closed
Study to Assess Change in Disease Symptoms in Adult Participants With Moderate to Severe Psoriasis Treated With Subcutaneous Risankizumab Injection According to Standard of Care
NCT04780516Psoriasis
AbbVie
Observational
141
Rehovot, Afula, Jerusalem, Safed, Ashkelon, Beersheba, Ramat Gan, Tel Aviv
2021-04-26
Active, closed
Long Term Safety and Efficacy of Butterfly Medical Prostatic Retraction Device in Benign Prostatic Hyperplasia (BPH) Patients Who Completed 12 Months of Follow-Up Post Implantation (Continuation Study for Study BM-011-IL)
NCT05330520BPH, BOO - Bladder Outflow Obstruction, Enlarged Prostate (BPH)
Butterfly Medical Ltd.
Not applicable
60
Petah Tikva, Safed
2021-02-10
Active, closed
Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer
NCT04464226Cancer
DrugDarolutamide
Bayer
Phase 3
402
Beersheba, Petah Tikva, Safed
2020-10-20
Active, closed
Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC
NCT04446117Metastatic Prostate Cancer, Prostate Adenocarcinoma
DrugsZytiga·Xtandi·Abiraterone·Abiraterone acetate
Exelixis
Phase 3
575
Haifa, Jerusalem, Petah Tikva, Ramat Gan, Safed, Tel Aviv
2020-10-19
Active, closed
A Study to Describe the Safety and Effectiveness of Venetoclax in Acute Myeloid Leukemia (AML) Patients (REVIVE Study)
NCT03987958Acute Myeloid Leukemia
AbbVie
Observational
100
Kfar Saba, Tel Aviv, Afula, Jerusalem, Safed, Beersheba, Ramat Gan, Haifa
2019-08-08
Active, closed
Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]
NCT03734029Breast Cancer
DrugsEribulin·Trastuzumab deruxtecan·Nab-paclitaxel·Capecitabine
Daiichi Sankyo
Phase 3
557
Haifa, Jerusalem, Petah Tikva, Ramat Gan, Rehovot, Safed, Tel Aviv
2018-12-27
Recruiting
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
NCT03486873Solid Tumors, Hematologic Malignancies
DrugsPembrolizumab/Favezelimab·) Berahyaluronidase alfa·Olaparib·Lenvatinib
Merck Sharp & Dohme LLC
Phase 3
3,500
Afula, Haifa, Jerusalem, Petah Tikva, Ramat Gan, Safed, Tel Aviv, แบ”erifin
2018-08-21
Active, closed
A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy
NCT03522246Epithelial Ovarian Cancer, Primary Peritoneal, Fallopian Tube Cancer, Newly Diagnosed
DrugsRucaparib·Nivolumab
pharmaand GmbH
Phase 3
1,097
Jerusalem, Kfar Saba, Nahariya, Ramat Gan, Safed, Tel Aviv
2018-05-14
Active, closed
A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic Medullary Thyroid Cancer
NCT01896479Medullary Thyroid Cancer
Exelixis
Phase 4
247
Jerusalem, Petah Tikva, Safed
2015-02-25
Recruiting
Computerized Registry of Patients With Venous Thromboembolism (RIETE)
NCT02832245Venous Thromboembolism
Manuel Monreal
Observational
120,000
Haifa, Jerusalem, Nahariya, Safed, Ramat Gan
2001-03
Rows per page Showing 1–34 of 34
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with an Israeli investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 26 September 2026. https://priyalifescience.com/clinical-trials-israel/city/safed

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Israel and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 2,428 studies in total at the last sync on 26 Sep 2026, 19:47 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 34 of those studies with a site in Safed.

How many clinical trials are recruiting in Safed?

11 of the 34 studies on this page are recruiting new participants as of the 26 Sep 2026, 19:47 UTC sync. A further 0 have not yet opened recruitment, 21 are active but closed to new participants, and 2 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Safed), 34 studies
PhaseStudiesRecruitingShare
Phase 316647.1%
Observational5114.7%
Phase 24111.8%
Not applicable328.8%
Phase 2/3318.8%
Phase 4205.9%
Phase 1/2102.9%

Most active sponsors

Lead sponsors with the most studies (Safed)
Lead sponsorStudiesRecruiting
AbbVie51
Merck Sharp & Dohme LLC32
Sanofi31
Agios Pharmaceuticals, Inc.20
Cytokinetics20
Dianthus Therapeutics21
Exelixis20
Janssen Research & Development, LLC21
Airway Therapeutics, Inc.11
AstraZeneca11
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.